Is There a Therapeutic Role for Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Metastatic Transitional Cell Carcinoma of the Bladder?

Abstract

Retroperitoneal lymph node dissection can be safely performed for metastatic transitional cell carcinoma. Retroperitoneal lymph node dissection has curative potential, particularly in patients with viable tumor in no more than 2 lymph nodes after chemotherapy.

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015

“…[265][266][267][268][269] C. Recommendation for patients in whom newly diagnosed bulky nodes are found at time of laparotomy i.…”

Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy

“…17 Sweeney and colleagues reported on the resection of clinically detectable retroperitoneal nodes in 11 patients after response to chemotherapy. Seven patients eventually developed recurrence outside of the original surgical field while 4 (36.4%) patients were rendered free of disease as a result of surgical consolidation.…”

647 Could a Salvage Surgery After Chemotherapy Have Clinical Impact on Cancer Survival in Patients With Metastatic Urothelial Carcinoma?

“…Cowles et al, writing on the concept of surgical treatment for metastatic urothelial cancer, reported a median 5-year survival rate for six patients following thoracotomy for solitary pulmonary metastatic lesion [7]. Due to the promising responses to chemotherapy, the therapeutic concept of surgery for metastatic urothelial cancer has been addressed again, a decade after the initial reports [8][9][10][11][12][13][14]. These reports support the therapeutic approach by surgical resection of metastatic lesion in patients with metastatic urothelial cancer.…”

“…Recently several authors have reported on the benefits of surgical resection of metastatic sites during a multidisciplinary approach for metastatic urothelial cancer [8][9][10][11][12][13][14]. Dodd et al [8] reported that a 5-yr overall survival rate of 33% was achieved in 50 patients with a major response to initial chemotherapy.…”